Transvenous adrenal destruction: clinical trials in patients with metastatic malignancy.
D000311:Adrenal Glands / Q000187:drug effects* / Q000502:physiology; D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage; D000368:Aged; D000772:Anesthesia, Local; D001667:Binding, Competitive; D001943:Breast Neoplasms / Q000628:therapy; D002404:Catheterization; D003287:Contrast Media / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000628:therapy*; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage*; D010690:Phlebography; D011183:Postoperative Complications; D011471:Prostatic Neoplasms / Q000628:therapy
D003287:Contrast Media; D009588:Nitrogen Mustard Compounds; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone